Louis Brenner MD - 15 Nov 2021 Form 4 Insider Report for Allena Pharmaceuticals, Inc.

Role: President and CEO, Director
Signature: /s/ Kevin Brennan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Nov 2021
Net transactions value: -$32,666
Form type: 4
Filing time: 17 Nov 2021, 16:00:29 UTC
Previous filing: 12 May 2021
Next filing: 02 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALNAQ	Common Stock	Sale	$32,666	-40,328	-12%	$0.8100^*	288,576	15 Nov 2021	Direct	F1
transaction	ALNAQ	Common Stock	Options Exercise		+125,582	+62%		328,904	15 Nov 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALNAQ	Restricted Stock Units	Options Exercise	$0	-125,582	-100%	$0.000000^*	0	15 Nov 2021	Common Stock	125,582		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	40% shall vest on May 10, 2021 and the remaining 60% shall vest on November 10, 2021, subject to the Reporting Person's continued service through each vesting date.